Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Triple negative breast neoplasms"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy
Bobae Shim, Min‐Sun Jin, Ji Hye Moon, In Ae Park, Han Suk Ryu
J Pathol Transl Med. 2018;52(6):369-377.   Published online October 1, 2018
DOI: https://doi.org/10.4132/jptm.2018.09.19
  • 12,178 View
  • 173 Download
  • 9 Web of Science
  • 11 Crossref
AbstractAbstract PDF
Background
Chemokine receptor CXC chemokine receptor type 4 (CXCR4) and its ligand CXC motif chemokine 12 (CXCL12; stromal cell-derived factor-1) are implicated in tumor growth, metastasis, and tumor cell-microenvironment interaction. A number of studies have reported that increased CXCR4 expression is associated with worse prognosis in triple-negative breast cancer (TNBC), but its prognostic significance has not been studied in TNBC patients treated with adjuvant chemotherapy.
Methods
Two hundred eighty-three TNBC patients who received adjuvant chemotherapy were retrospectively analyzed. Tissue microarray was constructed from formalinfixed, paraffin-embedded tumor tissue and immunohistochemistry for CXCR4 and CXCL12 was performed. Expression of each marker was compared with clinicopathologic characteristics and outcome.
Results
High cytoplasmic CXCR4 expression was associated with younger age (p = .008), higher histologic grade (p = .007) and lower pathologic stage (p = .045), while high CXCL12 expression was related to larger tumor size (p = .045), positive lymph node metastasis (p = .005), and higher pathologic stage (p = .017). The patients with high cytoplasmic CXCR4 experienced lower distant recurrence (p = .006) and better recurrence-free survival (RFS) (log-rank p = .020) after adjuvant chemotherapy. Cytoplasmic CXCR4 expression remained an independent factor of distant recurrence (p = .019) and RFS (p = .038) after multivariate analysis.
Conclusions
High cytoplasmic CXCR4 expression was associated with lower distant recurrence and better RFS in TNBC patients treated with adjuvant chemotherapy. This is the first study to correlate high CXCR4 expression to better TNBC prognosis, and the underlying mechanism needs to be elucidated in further studies.

Citations

Citations to this article as recorded by  
  • Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes
    Konstantinos Ntostoglou, Sofia D. P. Theodorou, Tanja Proctor, Ilias P. Nikas, Sinclair Awounvo, Athanasia Sepsa, Vassilis Georgoulias, Han Suk Ryu, Ioannis S. Pateras, Christos Kittas
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Unravelling the CXCL12/CXCR4 Axis in breast cancer: Insights into metastasis, microenvironment interactions, and therapeutic opportunities
    Priyanka Garg, Venkateswara Rao Jallepalli, Sonali Verma
    Human Gene.2024; 40: 201272.     CrossRef
  • New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer
    Neslihan Cabioglu, Semen Onder, Hüseyin Karatay, Aysel Bayram, Gizem Oner, Mustafa Tukenmez, Mahmut Muslumanoglu, Abdullah Igci, Ahmet Dinccag, Vahit Ozmen, Adnan Aydiner, Pınar Saip, Ekrem Yavuz
    Cancers.2024; 16(13): 2388.     CrossRef
  • Cancer-Associated-Fibroblast-Mediated Paracrine and Autocrine SDF-1/CXCR4 Signaling Promotes Stemness and Aggressiveness of Colorectal Cancers
    Chao-Yang Chen, Shih-Hsien Yang, Ping-Ying Chang, Su-Feng Chen, Shin Nieh, Wen-Yen Huang, Yu-Chun Lin, Oscar Kuang-Sheng Lee
    Cells.2024; 13(16): 1334.     CrossRef
  • Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study
    Shuai Lin, Yi Zheng, Meng Wang, Linghui Zhou, Yuyao Zhu, Yujiao Deng, Ying Wu, Dai Zhang, Na Li, Huafeng Kang, Zhijun Dai
    Molecular Biology Reports.2022; 49(3): 2255.     CrossRef
  • The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis
    Liping Qiu, Yuanyuan Xu, Hui Xu, Biyun Yu
    BMC Cancer.2022;[Epub]     CrossRef
  • Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm
    Mushtaq Ahmad Nengroo, Muqtada Ali Khan, Ayushi Verma, Dipak Datta
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(5): 188790.     CrossRef
  • Targeted dendrimers for antagonizing the migration and viability of NALM-6 lymphoblastic leukemia cells
    Chuda Chittasupho, Chaiyawat Aonsri, Witcha Imaram
    Bioorganic Chemistry.2021; 107: 104601.     CrossRef
  • CXCR4 and RANK Combination as a Predictor of Breast Cancer Bone Metastasis in Indonesia
    Yulian Erwin D
    Journal of Surgery and Surgical Research.2021; : 020.     CrossRef
  • CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
    Keywan Mortezaee
    Life Sciences.2020; 249: 117534.     CrossRef
  • Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma
    Irina Chifu, Britta Heinze, Carmina T. Fuss, Katharina Lang, Matthias Kroiss, Stefan Kircher, Cristina L. Ronchi, Barbara Altieri, Andreas Schirbel, Martin Fassnacht, Stefanie Hahner
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
Review
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer
Sung Gwe Ahn, Joon Jeong, SoonWon Hong, Woo Hee Jung
J Pathol Transl Med. 2015;49(5):355-363.   Published online August 17, 2015
DOI: https://doi.org/10.4132/jptm.2015.07.29
  • 13,302 View
  • 239 Download
  • 39 Web of Science
  • 32 Crossref
AbstractAbstract PDF
With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2–positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.

Citations

Citations to this article as recorded by  
  • Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer
    Hongyu Gao, Dengjie Ouyang, Xinyu Guan, Jiachi Xu, Qitong Chen, Liyun Zeng, Jian Pang, Qiongyan Zou, Ke Qian, Wenjun Yi
    BMC Cancer.2024;[Epub]     CrossRef
  • Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics
    Chenglu Jiang, Shengke Zhang, Lai Jiang, Zipei Chen, Haiqing Chen, Jinbang Huang, Jingyi Tang, Xiufang Luo, Guanhu Yang, Jie Liu, Hao Chi
    Environmental Toxicology.2024; 39(6): 3448.     CrossRef
  • Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
    Uiju Cho, Soyoung Im, Hyung Soon Park
    Journal of Pathology and Translational Medicine.2024; 58(2): 49.     CrossRef
  • Predictive and Prognostic Role of Tumor‐Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy
    Gaurav Agarwal, K. M. M. Vishvak Chanthar, Shweta Katiyar, Niraj Kumari, Narendra Krishnani, M. Sabaretnam, Gyan Chand, Anjali Mishra, Punita Lal
    World Journal of Surgery.2023; 47(5): 1238.     CrossRef
  • The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
    Ruonan Li, Lili Cao
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Using Self-Assembling ADDomer Platform to Display B and T Epitopes of Type O Foot-and-Mouth Disease Virus
    Chaowei Luo, Quanhui Yan, Juncong Huang, Jiameng Liu, Yuwan Li, Keke Wu, Bingke Li, Mingqiu Zhao, Shuangqi Fan, Hongxing Ding, Jinding Chen
    Viruses.2022; 14(8): 1810.     CrossRef
  • Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
    Guilan Shi, Megan Scott, Cathryn G. Mangiamele, Richard Heller
    Pharmaceutics.2022; 14(11): 2429.     CrossRef
  • Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy
    Bacinschi Xenia Elena, Laurentia Nicoleta Gales, Anca Florina Zgura, Laura Iliescu, Rodica Maricela Anghel, Bogdan Haineala, Xiaosheng Wang
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma
    Kyung Un Choi, Ahrong Kim, Jee Yeon Kim, Ki Hyung Kim, Chungsu Hwang, So Jung Lee, Won Young Park, Sejin Jung, Hye Jeong Choi, Kyungbin Kim
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review


    Weilin Xu, Xiu Chen, Fei Deng, Jian Zhang, Wei Zhang, Jinhai Tang
    OncoTargets and Therapy.2020; Volume 13: 5887.     CrossRef
  • Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
    Sandra V. Fernandez, Alexander W. MacFarlane, Mowafaq Jillab, Maria F. Arisi, Jennifer Yearley, Lakshmanan Annamalai, Yulan Gong, Kathy Q. Cai, R. Katherine Alpaugh, Massimo Cristofanilli, Kerry S. Campbell
    Breast Cancer Research.2020;[Epub]     CrossRef
  • Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
    C. Van Berckelaer, C. Rypens, P. van Dam, L. Pouillon, M. Parizel, K. A. Schats, M. Kockx, W. A. A. Tjalma, P. Vermeulen, S. van Laere, F. Bertucci, C. Colpaert, L. Dirix
    Breast Cancer Research.2019;[Epub]     CrossRef
  • The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status
    Anna Glajcar, Joanna Szpor, Diana Hodorowicz-Zaniewska, Katarzyna Ewa Tyrak, Krzysztof Okoń
    Virchows Archiv.2019; 475(1): 13.     CrossRef
  • Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
    Ana S. Leal, Kayla Zydeck, Sarah Carapellucci, Lyndsey A. Reich, Di Zhang, Jessica A. Moerland, Michael B. Sporn, Karen T. Liby
    npj Breast Cancer.2019;[Epub]     CrossRef
  • Stromal tumor‑infiltrating lymphocytes evaluated on H&E‑stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma
    Chungsu Hwang, So Lee, Jung Lee, Ki Kim, Dong Suh, Byung‑Su Kwon, Kyung Choi
    Oncology Letters.2019;[Epub]     CrossRef
  • The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
    Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, Mitsugu Yamamoto, Masako Sato, Ken-ichi Watanabe, Katsushige Yamashiro, Masato Takahashi
    Breast Cancer.2018; 25(1): 34.     CrossRef
  • Triple negative breast cancer – prognostic role of immune-related factors: a systematic review
    Elisabeth Specht Stovgaard, Dorte Nielsen, Estrid Hogdall, Eva Balslev
    Acta Oncologica.2018; 57(1): 74.     CrossRef
  • Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells
    Julian Gomez-Cambronero
    Cancer and Metastasis Reviews.2018; 37(2-3): 491.     CrossRef
  • Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers
    So Jeong Lee, Cheong-Soo Hwang, Young-Keum Kim, Hyun Jung Lee, Sang-Jeong Ahn, Nari Shin, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Do Youn Park, Chang Hun Lee, Gi Young Huh, Mi Young Sol, Hee Jin Lee, Gyungyub Gong, Jee Yeon Kim, Ahrong Kim
    Cancer Research and Treatment.2017; 49(2): 313.     CrossRef
  • Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes
    Joo Young Kim, Sun-Hee Heo, Seul Ki Choi, In Hye Song, In Ah Park, Young-Ae Kim, Hye Seon Park, Suk Young Park, Won Seon Bang, Gyungyub Gong, Hee Jin Lee
    Virchows Archiv.2017; 470(4): 381.     CrossRef
  • Whole Slide Imaging for Analytical Anatomic Pathology and Telepathology: Practical Applications Today, Promises, and Perils
    Alton Brad Farris, Cynthia Cohen, Thomas E. Rogers, Geoffrey H. Smith
    Archives of Pathology & Laboratory Medicine.2017; 141(4): 542.     CrossRef
  • Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility
    Andrea Ravelli, Giandomenico Roviello, Daniele Cretella, Andrea Cavazzoni, Alessandra Biondi, Maria Rosa Cappelletti, Laura Zanotti, Giuseppina Ferrero, Marco Ungari, Fabrizio Zanconati, Alberto Bottini, Roberta Alfieri, Pier Giorgio Petronini, Daniele Ge
    Tumor Biology.2017; 39(4): 101042831769502.     CrossRef
  • Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
    In Hye Song, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, In Ah Park, Young-Ae Kim, Suk Young Park, Jin Roh, Gyungyub Gong, Hee Jin Lee
    Cancer Research and Treatment.2017; 49(2): 399.     CrossRef
  • Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?
    Weiwei Zhao, Peng Wang, Huixun Jia, Menglei Chen, Xiaoli Gu, Minghui Liu, Zhe Zhang, Wenwu Cheng, Zhenyu Wu
    BMC Cancer.2017;[Epub]     CrossRef
  • Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
    Ahrong Kim, So Jeong Lee, Young Keum Kim, Won Young Park, Do Youn Park, Jee Yeon Kim, Chang Hun Lee, Gyungyub Gong, Gi Yeong Huh, Kyung Un Choi
    Scientific Reports.2017;[Epub]     CrossRef
  • Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer
    Kyueng-Whan Min, Dong-Hoon Kim, Sung-Im Do, Seoung Wan Chae, Kyungeun Kim, Jin Hee Sohn, Jung-Soo Pyo, Hyun Joo Lee, Dong Hyun Kim, Sukjoong Oh, Seon Hyeong Choi, Yong Lai Park, Chan Heun Park, Eun-Kyung Kim, Mi Jung Kwon, Jinwon Seo, Kyoung Min Moon
    Virchows Archiv.2016; 468(4): 409.     CrossRef
  • Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor‐infiltrating lymphocytes (TILs) in breast cancer
    Hee Jin Lee, Ahrong Kim, In Hye Song, In Ah Park, Jong Han Yu, Jin Hee Ahn, Gyungyub Gong
    Pathology International.2016; 66(4): 202.     CrossRef
  • Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy
    Kyu-pyo Kim, Hun Jung
    Translational and Clinical Pharmacology.2016; 24(1): 7.     CrossRef
  • The next level of 3D tumour models: immunocompetence
    Agata Nyga, Joana Neves, Katerina Stamati, Marilena Loizidou, Mark Emberton, Umber Cheema
    Drug Discovery Today.2016; 21(9): 1421.     CrossRef
  • An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes
    Ahrong Kim, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee
    American Journal of Clinical Pathology.2016; 146(1): 137.     CrossRef
  • High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer
    Kyueng-Whan Min, Dong-Hoon Kim, Sung-Im Do, Jung-Soo Pyo, Seoung Wan Chae, Jin Hee Sohn, Kyungeun Kim, Hyun Joo Lee, Dong Hyun Kim, Sukjoong Oh, Seon Hyeong Choi, Yong Lai Park, Chan Heun Park, Mi Jung Kwon, Kyoung Min Moon
    Postgraduate Medical Journal.2016; 92(1094): 707.     CrossRef
  • Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Changro Lee, Seho Park, Joo Heung Kim, Sung Mook Lim, Hyung Seok Park, Seung Il Kim, Byeong-Woo Park
    Journal of Breast Cancer.2016; 19(4): 385.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP